To evaluate methods for detection of genital human papillomavirus (HPV) DNA in men, samples were obtained from 3 consecutive groups of 10 men attending a sexually transmitted disease clinic by use of (1) a salinewetted Dacron swab alone, (2) a saline-wetted cytobrush, or (3) emery paper (600A-grit Wetordry Tri-M-ite; 3M) abrasion followed by a saline-wetted Dacron swab. By use of a polymerase chain reaction-based assay, 45% of emery-paper samples were found to be positive for b-globin, compared with 23% of swab-alone and 0% of cytobrush samples. Subsequently, emery paper and saline-wetted Dacron swabs were used to obtain penile shaft, glans, foreskin, and scrotum samples from 318 male university students. Urine samples were also obtained. Of 1323 samples tested, 1288 (97%) were found to be positive for b-globin. HPV DNA was detected in samples from 104 men (33%): 24% from the penile shaft, 16% from the glans, 28% from the foreskin, 17% from the scrotum, and 6% in urine. The HPV prevalence was similar for circumcised and uncircumcised men. Testing multiple sites increased the number of men for whom HPV DNA was detected.
italia, and the sensitivity of the assay used for detection of HPV DNA.
Some studies have examined HPV prevalence among male partners of women attending sexually transmitted disease (STD) clinics or among male partners of women with cervical intraepithelial neoplasia and/or genital warts [5] [6] [7] [8] [9] [10] [11] [12] . Others predominantly involved asymptomatic men from a sample of the population [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . In these studies, the highest reported prevalences of HPV (28%-76%) tended to be among older men with a higher average number of sex partners [13, [15] [16] [17] [18] [19] 22] . Among seemingly lower-risk populations, one study of 108 enrolled Swedish Army conscripts, 18-23 years old, which used polymerase chain reaction (PCR)-based testing of tissue obtained by biopsy from penile epithelium and urethral cytobrush samples, reported an overall HPV prevalence of 30% [20] . Another study included 27 sexually active students, 14-20 years old, and reported an estimated HPV prevalence of 23% [15] .
Techniques for sampling exfoliated cells from genital surfaces on men have involved the use of a saline-wetted cotton-tipped or Dacron swab, cytobrush, Urobrush (Medscand), or Accellon Multi biosampler swab (Medscand) to sample various genital sites or a combination of sites, including the penile shaft, preputial cavity, glans, coronal sulcus, urethra, scrotum, anus, and rectum [6, 13, [15] [16] [17] [18] [20] [21] [22] [23] . Some studies of men have found HPV testing of urine samples to be promising, in terms of specimen adequacy and detection of HPV DNA by PCR assay [24] [25] [26] [27] [28] [29] [30] , whereas others report poor specimen adequacy and lack of HPV positivity in urine samples [15, [31] [32] . Urine cytologic testing of men does not appear to be effective for detection of the dysplasia and koilocytotic atypia that are characteristic of HPV [11] [12] 33] . HPV DNA testing of other samples obtained from the male reproductive tract, particularly semen, has shown conflicting results, with widely ranging prevalence estimates [10, 14, 19, 27, 31, [34] [35] [36] [37] . Other studies of male partners of women with genital HPV describe colposcopic criteria in acetowhite lesions of the penis. Peniscopy, used in conjunction with biopsy, histopathology, and subsequent PCR for detection of HPV DNA in tissue samples, has also been used to identify latent or subclinical disease [18, 20, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] . Problems associated with these techniques include insufficient collection of cells for detection of HPV DNA, by use of swabs and brushes; poor specificity with peniscopy [40, 42, 44, 48, 49] ; and discomfort among patients during peniscopy with biopsy. In addition, the use of acetic acid and a colposcope requires specific training and clinical experience on the part of the medical provider, and significant costs are associated with the procedure and training. The present investigations were designed (1) to evaluate 3 methods of sample collection for detection of HPV DNA in a small sample of young, sexually active men attending an STD clinic and, on the basis of these findings, (2) to screen a larger cohort of male university students by use of 1 sample collection method, to determine which genital sites require sampling, and to accurately assess HPV DNA prevalence.
SUBJECTS, MATERIALS, AND METHODS
STD clinic study description. After approval from the University of Washington's Human Subjects Division (HSD), 30 heterosexual men, 18-25 years old, attending the Public Health Seattle King County (PHSKC) STD clinic at Harborview Medical Center were consecutively approached to participate in the study, from 1 August to 30 October 2000. Of the 30 subjects asked to participate, none declined or were deemed to be ineligible to participate, and all gave written, informed consent. Men attended the clinic either for symptoms suggestive of an STD or for primary screening for STDs and HIV infection. The same medical provider completed all examinations and data collection. We recorded date of clinic visit, reason for visit (including any current genital symptoms), history of STDs or HIV infection, number of new and of all sex partners during the last 2 months, and history of sex with men, women, or both, as well as results from STD/HIV testing performed on the day of examination.
Three different sampling techniques were used for collection of cells from the glans, foreskin, penile shaft, and scrotum. Among uncircumcised men, the foreskin sample was defined as the area of skin exposed on the penile shaft after retracting the foreskin, extending up to and including the coronal sulcus. Samples were obtained from the first 10 men by use of a salinewetted sterile Dacron swab; from the next 10 men by use of a saline-wetted sterile cytobrush; and from the last 10 men by use of a small (2ϫ4-cm) piece of emery paper (600A-grit Wetordry Tri-M-ite; 3M) followed by use of a saline-wetted sterile Dacron swab. For the penile shaft sample, one half of the emery-paper strip was used to rub the dorsal surface, and the other half was used to rub the ventral surface. For the scrotum sample, one half of the emery-paper strip was used to rub the left scrotum, and the other half was used to rub the right scrotum. Genitalswab, cytobrush, and emery-paper samples for detection and typing of HPV DNA were placed into separate vials containing 1 mL of specimen-transport medium (STM; Digene Diagnostics). By use of a dry Dacron swab, cells from the perianal and external urethral meatus region were obtained from all subjects. A first-void urine sample was also obtained on the day of examination. Ten milliliters of urine was poured into a separate vial and stored at room temperature for up to 6 h before being sent to the laboratory. At the laboratory, the urine was promptly centrifuged for 5 min. The supernatant was poured off, and the remaining pellet was stored at Ϫ70ЊC until processing.
University of Washington study description. After approval from the HSD, 318 sexually active, undergraduate male students, 18-25 years old, attending the University of Washington gave written, informed consent and were enrolled from 3 May 2001 to 9 July 2002 at the University of Washington Hall Health Primary Care Clinic. All subjects were recruited either by a letter sent to their campus address or by word of mouth. A total of 3250 letters were sent between April 2001 and May 2002; 137 of 208 men who responded by phone were deemed to be eligible, and 126 enrolled. Of the men recruited by word of mouth, 185 of 197 who responded by phone were deemed to be eligible, and 181 enrolled. The most common reasons for ineligibility included age 125 years or no history of sexual activity. We recorded date of clinic visit, history of STDs or HIV infection, review of current symptoms related to the genital tract, number of new and all sex partners during the last 4 and 12 months, frequency of intercourse over the course of the last 4 months, and history of sex with men, women, or both, as well as results from STD/HIV testing performed on the day of examination.
On the basis of the results obtained from the STD clinic population, emery paper (600A-grit Wetordry Tri-M-ite) and a saline-wetted Dacron swab were used for collection of cells from the glans (up to and including the external opening of the meatus), foreskin, penile shaft, and scrotum, as defined above for the STD clinic study. One medical provider obtained the majority of samples. In the present study, the samples obtained by use of emery paper and swabs for detection and typing of HPV DNA were placed together into 1 mL of STM for each genital site. Perianal samples were not obtained from these students, since there was no HPV DNA detected from this site in the STD clinic population, and the majority of the men in the STD clinic sample reported discomfort and anxiety with sampling in this region. A first-void urine sample was also obtained. Immediately after urine samples were obtained, 10 mL was poured into a separate vial and centrifuged for 5 min. The supernatant was poured off, and the remaining pellet was immediately stored at Ϫ20ЊC and then was placed on dry ice and, within 24-48 h, was sent to the laboratory via a courier. On arrival at the laboratory, the pellet was stored at Ϫ70ЊC until processing.
DNA preparation. The STM samples were digested with 20 mg/mL protease K for 1 h at 37ЊC. For each sample, 400 mL was used to isolate DNA by QIAamp DNA blood mini column, following the manufacturer's protocol (Qiagen). In brief, each sample was digested with protease for 10 min at 56ЊC and then was loaded onto a QIAamp column. The column was washed, DNA was eluted in 50 mL of heated (70ЊC) Tris EDTA buffer, and the concentration was measured by a fluorometer.
PCR amplification and dot-blot hybridization. Each sample of DNA was amplified by use of HPV L1 consensus primers MY09, MY11, and HMB01 and b-globin primers PC04 and GH20. The amplification mixture contained 6 mmol/L MgCl 2 , 1ϫ PCR buffer II (AmpliTaq Gold; Roche Molecular Diagnostics), 7.5 U of Gold Taq DNA polymerase (AmpliTaq Gold; Roche Molecular Diagnostics), 200 mmol/L dNTPs, 50 pmol of MY09 and MY11 primers, 10 pmol of HMB01, PC04, and GH20 primers, and 5 mL of template DNA, in a final volume of 50 mL. The DNA was amplified by use of the following program: 9 min at 95ЊC; 30 s at 95ЊC, 60 s at 55ЊC, and 60 s at 72ЊC, for 40 cycles; and 10 min at 72ЊC. Ten microliters of PCR products was then dotted onto nylon filters and probed by use of biotin-labeled b-globin and HPV generic probes. Results were recorded with regard to whether the sample was found to be positive for b-globin and/or HPV. For the STD clinic study, samples were dot-blotted, regardless of the b-globin amplification result. For the University of Washington study, samples found to be negative for b-globin were considered to be insufficient for HPV DNA testing.
HPV typing by use of line-blot assay. Samples that were found to be positive for the generic HPV probe were typed by use of the line-blot assay developed by Roche Diagnostics. HPV DNA was amplified with biotinylated primer pools (PGMY09 and PGMY11), and b-globin was simultaneously amplified with biotinylated PC04 or GH20 [50] . The amplification mixture contained 4 mmol/L MgCl 2 , 1ϫ PCR buffer II, 7.5 U of Gold Taq DNA polymerase, 200 mmol/L dNTPs, 50 pmol of PGMY09 and PGMY11 primers, 1.25 pmol of PC04 and GH20 primers, and 5 mL of template DNA, in a final volume of 75 mL. The HPV was amplified using the following program: 9 min at 95ЊC; 30 s at 95ЊC, 60 s at 55ЊC, and 60 s at 72ЊC, for 40 cycles; and 5 min at 72ЊC. Then, 50 mL of PCR product was mixed with 50 mL of Amplicor denaturation solution. Seventy microliters of denatured PCR product was added to each well of an Amplicor typing tray containing 3 mL of preheated hybridization solution (4ϫ saline sodium phosphate EDTA [SSPE] and 0.5% SDS) and a strip containing b-globin and 27 HPV oligonucleotide probes (types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, [51] [52] [53] [54] [55] [56] [57] [58] [59] 66 , 68, 73, and 82-84). The tray was incubated for 30 min at 53ЊC and then was washed with 3 mL of washing solution (1ϫ SSPE and 0.1% SDS) briefly at room temperature and for 15 min at 53ЊC. After washing, 3 mL of Amplicor streptavidin-horseradish peroxidase conjugate was added, and the tray was incubated for 30 min at room temperature. The tray was washed twice with 3 mL of washing solution for 15 min at room temperature then briefly with 3 mL of citrate buffer. The substrate was prepared by mixing 0.01% H 2 O 2 and 0.1% ProClin in a 0.1 mol/L citrate solution with 0.1% tetramethylbenzidine in dimethylformamide. Three milliliters of substrate was added to each well, and the tray was incubated for 5 min at room temperature and then rinsed with distilled water. The results were recorded within 30 min. The typed results are not yet completed and, therefore, are not included in this report.
Distinction of methods for men attending an STD clinic, compared with those for university students. During and after the first study in which men attending an STD clinic were tested, we learned that (1) using emery paper for sample collection, (2) concentrating the DNA 5-fold during the DNA preparation, and (3) using QIAamp DNA blood mini columns during the DNA preparation all improved the sensitivity of detection of b-globin and HPV DNA in samples tested. All 3 methods mentioned above were, therefore, subsequently used for testing of the university population, whereas only the first method had been used for the STD clinic population. For the university population, we also performed an HPV sensitivity assay in which increasing amounts (30, 300, 1500, 3000, 15,000, and 30,000 cells) of HPV-16-positive cells (Siha cells) were mixed with HPV-negative cells (K562 cells), in a total 5 3 ϫ 10 volume of 0.6 mL of STM. Both DNA preparation and PCR amplification from these samples were performed using the same methods as those used for clinical samples mentioned above. Two to 10 HPV-16 copies/50 ng of total cellular DNA were detected (∼2000 HPV-negative cells).
Other STD testing. Screening for other STDs was performed at the PHSKC laboratory. Testing for gonorrhea was performed by culture using a urethral swab for collection of samples or by urine ligase chain reaction (LCR). Chlamydia testing was performed by urine LCR. Syphilis testing and HIV-1 screening were performed by serum rapid plasma reagin (RPR) test and ELISA, respectively. Serologic testing for herpes simplex virus types 1 and 2 (HSV-1/2) infection by use of an EIA was offered in the University of Washington study. After screening ∼298 men for HSV infection, HIV infection, syphilis, gonorrhea, and chlamydia and finding few positive results, as well as some presumed false-positive results for HSV-1/2 infection, we changed the protocol to routinely screen for HIV infection and chlamydia and screened for the others only if they were clinically indicated.
Statistical analysis. In the STD clinic study, the x 2 test was used to compare sampling methods for b-globin and HPV positivity by site, risk factors for acquisition of STDs, and demographic characteristics between groups. In the University of Washington study, the x 2 test was used to compare sampling methods for b-globin and HPV positivity by site and circumcision status.
was considered to be statistically significant. P ! .05 RESULTS STD clinic study. The mean age of the 30 men included in the STD clinic study was 22.6 years. Seventy-seven percent (23/ 30) of the men were white, 10% (3/30) were African American, 6.7% (2/30) were Asian, and 6.7% (2/30) were Latino. Each group of 10 men included 1 uncircumcised man. The mean number of sex partners during the last 12 months was 3. Fiftythree percent (16/30) of the men had no new sex partners during the last 2 months, 33% (10/30) had 1 new partner, 10% (3/30) had 2 new partners, and 3% (3/30) had 3 new partners. Evidence of genital warts, chlamydia, and gonorrhea on the day of examination was similar in each group of 10 men. Two men each (20%) in the groups in which samples were obtained by use of a saline-wetted Dacron swab alone and by use of a saline-wetted cytobrush and 1 (10%) in the group in which samples were obtained by use of emery paper plus a salinewetted Dacron swab had genital warts detected on the day of examination. One man each (10%) in the groups in which samples were obtained by use of a saline-wetted Dacron swab alone and by use of a saline-wetted cytobrush and 2 (20%) in the group in which samples were obtained by use of emery paper plus a saline-wetted Dacron swab was found to have chlamydia. One man each (10%) in the groups in which samples were obtained by use of a saline-wetted cytobrush alone and by use of emery paper plus a saline-wetted Dacron swab and none in the group in which samples were obtained by use of a saline-wetted Dacron swab alone was found to have gonorrhea. HIV and syphilis tests were negative for all participants.
Of 29 samples obtained by use of emery paper, 13 (45%) were found to be positive for b-globin, compared with 7 (23%) of 30 obtained by use of a saline-wetted Dacron swab alone. No samples obtained by use of a saline-wetted cytobrush were found to be positive for b-globin. Although the difference was not statistically significant, the yield for b-globin positivity was greatest when samples were obtained by use of emery paper from the penile shaft (70% positive vs. 30% positive by use of a saline-wetted Dacron swab alone).
The overall prevalence of detection of HPV DNA was 40% among the 10 men for whom samples were obtained by use of emery paper plus a saline-wetted Dacron swab, 40% among the 10 men for whom samples were obtained by use of a salinewetted Dacron swab alone, and 20% among the 10 men for whom samples were obtained by use of a saline-wetted cytobrush alone. Of the 3 uncircumcised men (1 from each group), none was found to be positive for HPV. Of 26 samples found to be positive for b-globin, only 1 each from the external meatus ( men) and urine ( men) had detectable HPV n p 28 n p 29 DNA. Only 1 sample from the perianal region was found to be positive for b-globin, and no samples from this site had detectable HPV DNA ( ). n p 30 University of Washington study. Of 318 men enrolled in this study, 1 was excluded because he was not able to provide a urine sample and because 2 samples, obtained from the glans and scrotum, were insufficient for analysis. The mean age of the 317 included men was 20.5 years. Eighty-one percent of men (7/317) were white, 6% (19/317) were Asian, 3% (11/317) were African American, 2% (7/317) were Latino, and 8% (24/ 317) were of other race. Eighty-one percent of men (258/317) were circumcised. The median lifetime number of sex partners was 4, and that during the last 4 months was 1. Five percent of men (16/317) had clinical evidence of genital warts on examination. Of those tested for gonorrhea and HIV infection, none were found to be positive. Twenty-six percent (77/296) and 3% (8/297) of men had HSV-1 and HSV-2 infection, respectively, detected by serum EIA; 1% (3/314) had chlamydia, detected by urine LCR; and 0.3% (1/298) had syphilis, detected by a reactive serum RPR, a reactive confirmatory agglutination assay for antibodies to Treponema pallidum, and a Venereal Disease Research Laboratory titer of 1:16. All 317 men tested for HPV had at least 2 samples sufficient for PCR analysis. Of men who had у2 sufficient samples, 33% (104/317) had HPV DNA detected at у1 site (table 1) . Excluding those men who had any insufficient samples or samples that were not tested, 35% (99/283) had HPV DNA detected at у1 site. Of 1323 samples tested (from 317 men), 215 (16%) were found to be positive for HPV DNA, including 77 (24%) from the penile shaft, 51 (16%) from the glans, 16 (28%) from the foreskin, 53 (17%) from the scrotum, and 18 (6%) from urine (table 2). Only 3% of samples (35/1323) were found to be negative for b-globin. These 35 samples were obtained from 30 (9.5%) of the 317 men and included 6 from the penile shaft, 8 from the glans, 19 from the scrotum, and 1 each from the foreskin and urine.
Of the 82 circumcised men who were found to be positive for HPV DNA at any genital site, 63 (77%) had HPV DNA detected in the sample from the penile shaft, 39 (48%) had HPV DNA detected in the sample from the glans, 43 (52%) had HPV DNA detected in the sample from the scrotum, and 13 (16%) had HPV DNA detected in the urine sample (table  3) . Of the 19 circumcised men (23%) with penile shaft samples found to be negative for HPV DNA, 7 had HPV DNA detected in the sample from the glans, 7 had HPV DNA detected in the sample from the scrotum, and 8 had HPV DNA detected in the urine sample. Of the 17 uncircumcised men who were found to be positive for HPV DNA at any genital site, 9 (53%) had HPV DNA detected in the sample from the penile shaft, 11 (65%) had HPV DNA detected in the sample from the glans, 15 (88%) had HPV DNA detected in the sample from the foreskin, 9 (53%) had HPV DNA detected in the sample from the scrotum, and 5 (29%) had HPV DNA detected in the urine sample (table 4) . Among the 8 uncircumcised men who had HPV DNA detected at any site but whose penile shaft samples were found to be negative, the foreskin was found to be positive for HPV DNA in 6 samples, and the glans was found to be positive for HPV DNA in 1 sample. Interestingly, the HPV DNA prevalence for circumcised men was similar to that for uncircumcised men (31% [82/258] vs. 29% [17/59];
). P p .66
DISCUSSION
In the STD clinic population, we found that the method using emery paper plus a saline-wetted Dacron swab was the most sensitive for detection of b-globin and was at least as sensitive for detection of HPV DNA as the method using saline-wetted Dacron swab alone. Thus, the method using emery paper plus a swab was used for evaluation of appropriate genital sites for sample collection in the University of Washington study population. Of the samples obtained from the 317 men included in the University of Washington study analysis, only 3% were insufficient for detection of HPV DNA by use of a PCR-based assay, a percentage that is similar to that reported in other studies in which exfoliated cells were obtained by use of a swab on the penile shaft, glans, or coronal sulcus [5, 9, 13, 15] . Baken et al. [9] reported that only 4% of 50 samples obtained by use of a Dacron swab were found to be negative for b-globin, 
a Of 258 circumcised men tested, 86 had HPV DNA detected at any site, and 172 had no HPV DNA detected. Four HPV-positive men were excluded: 2 men did not have a urine sample obtained, and 2 men each had 1 insufficient sample from urine and the scrotum. Twenty-one HPV-negative men were excluded because all 4 genital samples were not sufficient for PCR analysis. 
a Of 59 uncircumcised men tested, 18 had HPV DNA detected at any site, and 41 had no HPV DNA detected. Nine men were excluded: 1 HPV-positive man was excluded for insufficient sample from the glans, and 8 HPV-negative men were excluded because all 5 genital samples were not sufficient for PCR analysis.
compared with an insufficiency rate of 25.1% of 1520 samples obtained by use of a wetted cotton-tipped swab in the study by Castellsagué et al. [5] . In Lazcano-Ponce et al.'s study of Mexican men [15] , 5% of genital samples obtained by use of an Accellon Multi biosampler swab (Medscand) were found to be negative for b-globin. In Svare et al.'s study of Danish persons who attended an STD clinic [13] , samples obtained from the penile shaft, glans, coronal sulcus, scrotum, and perianal region were all placed in the same tube, and this combined sample from all men was sufficient for analysis. Combining all samples in 1 tube may have increased the number and concentration of cells; however, this strategy does not permit evaluation of detection of HPV DNA at different genital sites. In our pilot study of 30 men attending an STD clinic, we found that 13 (6%) of 206 samples from 7 men (23%) were positive for HPV DNA but were negative for b-globin, raising the questions of (1) whether b-globin amplification in genital samples obtained from men is necessary for detection of HPV DNA and (2) whether our methods for DNA amplification were relatively insensitive. Using more-sensitive laboratory methods for DNA amplification, including Qiagen columns and DNA concentration for processing samples obtained from the university student population, we did not find any samples that were HPV DNA positive and b-globin negative. Others have shown that desquamated, often anucleated, cornified cells that are continuously shed from the stratum corneum may be packed with HPV virions [51] , suggesting that the presence of nuclear material containing the b-globin gene is not essential for detecting HPV DNA in the desquamating layer of differentiated squamous epithelium. In the present study, we found that the scrotum yielded the largest percentage of insufficient samples. This may be due to the fact that scrotal skin is heavily keratinized, often with hair covering much of the region, making it difficult to obtain exfoliated cells from the surface. Using a highly sensitive sampling technique and a PCR-based assay capable of detecting 2-10 HPV-16 copies/50 ng of total cellular DNA (∼2000 HPV-negative cells) and excluding men with any b-globin-negative samples or samples that were not tested, we found an HPV prevalence of 35%. A comparison of the HPV prevalence for the subset of 213 male students (18-20 years old) with that of 418 female students (18-20 years old) from the same university who provided cervical and vulvovaginal samples for HPV DNA testing revealed the same HPV prevalence: 28% (Q.F., N.K., and L.K., unpublished data).
Testing multiple sites increased the likelihood of detecting HPV DNA, especially among circumcised men. We observed similar percentages of HPV DNA positivity among circumcised and uncircumcised men. Aynaud et al. [38] also found no difference in HPV prevalence (detected by peniscopy and urethroscopy with urethral biopsies) among 219 circumcised and uncircumcised, heterosexual, HIV-negative male partners of women with genital HPV infection. However, there are at least 2 other recently published reports [5, 13] showing lower rates of detection of HPV DNA among circumcised men, compared with uncircumcised men. In Castellsagué et al.'s study [5] , genital samples from men were obtained only from the glans, the coronal sulcus, and the distal urethra, whereas, in both the present study and the study reported by Aynaud et al. [38] , samples were also obtained from the penile shaft, which appears to be critical for HPV testing, especially among circumcised men. In the present study, if only samples from the glans and foreskin had been tested, only 17% of circumcised men (39/ 233) and 32% of uncircumcised men (16/50) would have had HPV DNA detected, resulting in an overall prevalence of only 19% (55/283) and a significant difference in HPV positivity between circumcised and uncircumcised men. Thus, failure to obtain samples from other sites, such as the penile shaft and the scrotum, appears to substantially reduce the number of genital HPV infections detected among circumcised men.
Further studies evaluating the most appropriate method for collection of genital samples among a cohort of men that is most representative of the general population, with specific attention being placed on the issue of b-globin positivity and the acceptability of the procedure, are needed. Also, the number of times testing should occur for optimal detection of HPV DNA among men is unknown. For example, one study [16] reports that consecutive genital sampling on different days over a short period of time results in a nearly 3-fold increase in the number of men for whom HPV DNA is detected.
A screening test capable of detecting subclinical genital HPV infection in men without great cost or discomfort to patients would be of great value. The method using emery paper plus a saline-wetted Dacron swab is both easy for clinicians to perform and inexpensive. This would have direct implications for whom and where the testing could be provided. Since the American Society for Colposcopy and Cervical Pathology [52] has recommended the use of reflex HPV DNA testing for the triage and management of women with atypical squamous cells of undetermined significance Pap tests, an increasing number of female patients are requesting HPV testing for themselves and their partners. Another use may be for HPV testing in clinical trials of HPV vaccines among men and in surveillance of genital HPV types after HPV vaccination becomes widely available in the United States. In some situations, HPV testing of men may be useful for identifying female partners who are at increased risk for development of cervical cancer. For example, in a study of key risk factors for cervical cancer in Spain, the authors report an increase of up to 9.5-fold in the odds of cervical cancer among monogamous women whose husbands had high-risk HPV types detected by use of a wetted cottontipped swab on the glans, coronal sulcus, and distal urethra and by PCR-based testing for HPV DNA [8] .
HPV testing of urethral-swab or semen samples, which were not obtained in the present study, has been previously studied. In studies performed on predominantly asymptomatic men from whom urethral samples were obtained and tested for HPV DNA by a PCR-based assay, the HPV prevalence detected from the urethra ranged from 12% to 31% [18, 20, [24] [25] [26] . In a study of 75 men who attended an STD clinic, ∼18% had HPV DNA-positive urethral samples, but only 1 had a positive urethral sample and negative penile shaft, glans, scrotum, and urine samples (C. Wheeler and J. Perez, personal communication). Furthermore, none was found to be positive for HPV DNA in only urine or semen (C. Wheeler and J. Perez, personal communication). Thus, when compared with testing of samples from other sites-such as the penile shaft, scrotum, and glanstesting a urethral or semen sample appears to be low yield. We are not aware of any other published data that compare semen with other genital sites for detection of HPV DNA by a PCRbased assay.
In conclusion, the method using emery paper plus a salinewetted Dacron swab proved to be both easy and inexpensive to perform and provided adequate cellular material, by measurement of the b-globin gene, in most of the samples. Testing multiple sites, especially among circumcised men, increased the number of men who were found to be positive for genital HPV by a PCR-based assay. For HPV screening of circumcised men, we recommend that multiple sites-including the penile shaft, glans, coronal sulcus, scrotum, and urine-be tested by use of a sensitive sampling technique, such as the method using emery paper plus a saline-wetted Dacron swab. Though testing of urine samples identified only an additional 7% of men with HPV DNA in our study, we still recommend its use in this population, since they are easy to obtain. To decrease costs, the urine sample could be stored in the laboratory and tested only for those men who are found to be negative for HPV DNA at all other genital sites. More data are needed with regard to the optimal way to process urine samples for HPV DNA testing in the laboratory. For HPV screening of uncircumcised men, we recommend that samples from the internal foreskin, which could be included with the glans and coronal sulcus in 1 sample, and from the penile shaft, including the external foreskin, be obtained for HPV DNA testing in this population. In the present study, testing additional sites, such as the scrotum and urine, did not yield an increase in HPV positivity among uncircumcised men.
